4SC AG: 4SC provides Q1 2021 update

4SC AG (4SC, FSE Prime Standard: VSC) today published the Q1 Announcement 2021, presenting all material developments up to 31 March 2021 and the Company’s current outlook. The full communication is available for download on 4SC’s website (http://www.4sc.com/investors/investor-information/financial-reports/). Jason Loveridge, Read More

Atopic dermatitis app Nia gets further supporter with Sanofi Genzyme

Atopic dermatitis is one of the most widespread chronic skin diseases. Painful itching, dry skin and redness make life difficult for atopic dermatitis patients. This is where the atopic dermatitis app Nia comes in: it supports the chronically ill and Read More

4SC to present at the virtual 10th World Congress of Melanoma and 17th EADO Congress

4SC AG (4SC, FSE Prime Standard: VSC) will attend and present at the virtual 10th World Congress of Melanoma and 17th EADO Congress, from the 15-17 April 2021. A summary of the key clinical trial updates are listed below: * Read More

4SC präsentiert auf dem virtuellen 10th World Congress of Melanoma and 17th EADO Congress

Die 4SC AG (4SC, FSE Prime Standard: VSC) wird am virtuellen "10th World Congress of Melanoma and 17th EADO Congress", 15.-17. April 2021 teilnehmen und dort präsentieren. Eine Zusammenfassung der wichtigsten Updates zu klinischen Studien ist unten aufgeführt: * Trial Read More

ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases

– ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Read More

Kombination von Copanlisib und Rituximab verlängert progressionsfreies Überleben von Patienten mit rezidivierten indolenten Non-Hodgkin-Lymphomen signifikant

Copanlisib ist der erste PI3K-Inhibitor, der in Kombination mit Rituximab bei Patienten mit rezidivierten indolenten Non-Hodgkin-Lymphomen (iNHL) eine überlegene Wirksamkeit im Vergleich zu Rituximab und Placebo zeigt / Die Phase-III-Studie CHRONOS-3 zeigte, dass die Kombination von Copanlisib und Rituximab das Read More

Transparency Market Research (TMR) has published a new report on the corneal topographers market for the forecast period of 2019-2027

According to the report, the global corneal topographers market was valued at ~US$ 920 Mn in 2018, and is projected to expand at a CAGR of 5% from 2019 to 2027. The global corneal topographers market is driven by an Read More

Lonza Completes Divestment of Two Sites to NextPharma

Completion of sale of Lonza sites in Ploermel (FR) and Edinburgh (UK) A seamless ownership transfer process remains a priority Quote from Gordon Bates, President and Head of Small Molecules, Lonza: “The strategic divestment of our Ploermel and Edinburgh sites Read More